Results 21 to 30 of about 23,403 (218)

Pharmacogenetics of loop diuretics

Clinical Pharmacology & Therapeutics, 2004
Objective Genetic variability in pharmacokinetics and pharmacodynamics of diuretics is incompletely studied. We compared the extent of variability in different loop diuretics and determined to what extent this is influenced by polymorphisms in candidate genes. Methods Single oral doses of bumetanide 2 mg, furosemide 80 mg and torasemide 10
Vormfelde, Stefan Viktor, Zirk, A., Westermann, J., Torn, M., Tuchen, F., Toliat, Mohammad Reza, Brockmoeller, Juergen   +6 more
openaire   +2 more sources

Loop diuretics have anxiolytic effects in rat models of conditioned anxiety. [PDF]

PLoS ONE, 2012
A number of antiepileptic medications that modulate GABA(A) mediated synaptic transmission are anxiolytic. The loop diuretics furosemide (Lasix) and bumetanide (Bumex) are thought to have antiepileptic properties.
Andrew D Krystal, Janice Sutherland, Daryl W Hochman   +2 more
doaj   +1 more source

Loop Diuretics in Clinical Practice [PDF]

Electrolytes & Blood Pressure, 2015
Diuretics are commonly used to control edema across various clinical fields. Diuretics inhibit sodium reabsorption in specific renal tubules, resulting in increased urinary sodium and water excretion. Loop diuretics are the most potent diuretics. In this article, we review five important aspects of loop diuretics, in particular furosemide, which must ...
Oh, Se Won, Han, Sang Youb
openaire   +2 more sources

Outcomes Associated With a Strategy of Adjuvant Metolazone or High‐Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background In acute decompensated heart failure, guidelines recommend increasing loop diuretic dose or adding a thiazide diuretic when diuresis is inadequate.
Meredith A. Brisco‐Bacik, Jozine M. ter Maaten, Steven R. Houser, Natasha A. Vedage, Veena Rao, Tariq Ahmad, F. Perry Wilson, Jeffrey M. Testani   +7 more
doaj   +1 more source

Use of Loop Diuretics is Associated with Increased Mortality in Patients with Suspected Coronary Artery Disease, but without Systolic Heart Failure or Renal Impairment: An Observational Study Using Propensity Score Matching.

PLoS ONE, 2015
BACKGROUND:Loop diuretics are widely used in patients with heart and renal failure, as well as to treat hypertension and peripheral edema. However, there are no randomized, controlled trials (RCT) evaluating their long term safety, and several ...
Hall Schartum-Hansen, Kjetil H Løland, Gard F T Svingen, Reinhard Seifert, Eva R Pedersen, Jan E Nordrehaug, Øyvind Bleie, Marta Ebbing, Christ Berge, Dennis W T Nilsen, Ottar Nygård   +10 more
doaj   +1 more source

Heart Failure Drug Class Effects on 30-Day Readmission Rates in Patients with Heart Failure with Preserved Ejection Fraction: A Retrospective Single Center Study

Medicines, 2020
Background: The pharmacologic management of heart failure with preserved ejection fraction (HFpEF) involves far fewer options with demonstrated additional benefit.
Priyanka Parajuli, Odalys Estefania Lara-Garcia, Manjari Rani Regmi, Warren Skoza, Mukul Bhattarai, Abhishek Kulkarni, Robert Leonard Robinson   +6 more
doaj   +1 more source

Sequential Blockade with Loop Diuretics and Acetazolamide: A Novel Strategy in Acute Heart Failure

Journal of the Indian Academy of Geriatrics
Acute decompensated heart failure (HF) is the most common form of acute HF (AHF) and presents with systemic congestion due to left ventricular dysfunction with sodium and water retention.
Nitin R. Gaikwad, Madhusudan Prasad Singh, Alok Singh   +2 more
doaj   +1 more source

Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial

Kidney Diseases
Introduction: VERTIS CV was a placebo-controlled cardiovascular (CV) outcome trial evaluating the sodium-glucose cotransporter 2 inhibitor ertugliflozin in patients with type 2 diabetes and established atherosclerotic CV disease.
David Z.I. Cherney, Robert Frederich, Richard E. Pratley, Francesco Cosentino, Samuel Dagogo-Jack, Annpey Pong, Ira Gantz, Nilo B. Cater, James P. Mancuso, Urszula Masiukiewicz, Christopher P. Cannon   +10 more
doaj   +1 more source

BENFOTHIAMINE ADMINISTRATION IN PATIENTS WITH DILATED CARDIOMYOPATHY AND ADVANCED HEART FAILURE WITH CHRONIC DIURETIC TREATMENT

Studia Universitatis Babes-Bolyai Chemia, 2017
It is well known that long term administration of high dose loop diuretics in patients with heart failure, may in some cases aggravate the cardiac failure symptoms. Part of this effect may be due to thiamine depletion secondary to diuretics use. The aim
Dana-Adriana ILUȚIU-VARVARA, Dan RĂDULESCU, Valer Ioan DONCA   +2 more
doaj   +1 more source

Current Clinical and Pharmacological Approaches to the Prescription of Loop Diuretics in Patients with Chronic Heart Failure

Рациональная фармакотерапия в кардиологии, 2020
Heart failure (HF) is a growing public health problem with an estimated prevalence of 38 million patients worldwide. Congestion and formation of edema – are typical symptoms of heart failure. Diuretics are the mainstay of therapy in heart failure and are
N. M. Gafurova, E. V. Shikh, O. D. Ostroumova   +2 more
doaj   +1 more source